RVMD ▼ -2.4% - Revolution Medicines, Inc.
$RVMD - European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
16-NOV-2026 01:00 PM ET
Share this post
More filings for $RVMD
RVMD ▼ -3.0% - Revolution Medicines, Inc.Nov 16, 2026RVMD - Revolution Medicines, Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026RVMD ▲ +13.2% - Revolution Medicines, Inc.Nov 4, 2026RVMD ▲ +10.6% - Revolution Medicines, Inc.Nov 4, 2026RVMD ▲ +12.2% - Revolution Medicines, Inc.Nov 4, 2026RVMD ▲ +12.2% - Revolution Medicines, Inc.Nov 4, 2026
View full $RVMD filing history →💬 Comments
Loading comments…
Leave a comment
